Buscapina Compositum is a combination medicine, commonly used when short-term symptomatic assistance is needed for managing spasmodic pain associated with acute or episodic changes. This combination is applied across domains where additional symptomatic support is needed.

The medicine is utilized for easing symptoms that interfere with daily comfort in conditions presenting with systemic or localized discomfort. The specific conditions where this medicine is commonly used include spasmodic pain related to stomach and intestinal illness, colic-type pain, functional disorders of the biliary and urinary tracts, and problems affecting the female genital organs, such as dysmenorrhea.

The combination contributes to improved comfort during periods of heightened symptoms. The combination helps maintain a sense of stability when symptoms are more noticeable, providing supportive relief when symptoms create noticeable functional strain. It helps ease the overall symptom burden during difficult episodes, offering assistance in managing pain and discomfort associated with acute or disruptive episodes.

Quick Fact: May assist with symptomatic relief for Spasmodic Cramps

Regulatory References

1. European Medicines Agency Pharmacovigilance Plan

Who Can and Cannot Use Buscapina Compositum?

The population eligibility for Buscapina Compositum is strictly defined by regulatory documents, largely based on the contraindications related to its two components, Hyoscine Butylbromide and Sodium Metamizole.

---

Absolute Contraindications

Use of this medicine is prohibited for patients with a known hypersensitivity to its active ingredients or other pyrazolone derivatives. It is strictly contraindicated in individuals with pre-existing conditions affecting the blood system, such as bone marrow function impairment or agranulocytosis.

It must also not be used by patients with narrow-angle glaucoma, Myasthenia Gravis, mechanical stenosis of the gastrointestinal tract, paralytic ileus, or acute intermittent hepatic porphyria.

---

Age and Physiological Restrictions

Population Group	Regulatory Status
Children	Generally not recommended or contraindicated below 10–15 years, depending on formulation.
Pregnancy	Contraindicated in the first and third trimesters. Not recommended during the second.
Lactation	Contraindicated or not recommended.

Conditional use is required for patients with impaired renal function or impaired hepatic function, due to the potential for reduced elimination of the drug and its metabolites. Older adults also require caution due to increased sensitivity to anticholinergic effects.

The official regulatory profile for Buscapina Compositum documents several distinct interaction patterns. Pharmacodynamic interactions associated with the Hyoscine Butylbromide component involve the intensification of effects when co-administered with other anticholinergic agents, such as certain tricyclic antidepressants, antihistamines, or antipsychotics. Conversely, the co-administration of Dopamine Antagonists, like Metoclopramide, may result in a diminution of the effects of both medicines on gastrointestinal motility. The Metamizole component contributes to an additive adverse effect profile, specifically an increased risk of gastrointestinal bleeding when combined with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin.

A pharmacokinetic interaction is documented with Hepatic Microsomal Enzyme Inducers (e.g., Barbiturates, Phenylbutazone), which are officially stated to reduce the half-life and duration of action of Metamizole. The regulatory information also defines two critical restrictions: first, the intramuscular injection route is prohibited for patients receiving Anticoagulant Drugs due to the potential for intramuscular haematoma. Second, an administration timing requirement states that oral Antacids or Adsorbent Anti-Diarrheals must be separated and taken at least one hour before the oral form of this medicine. Finally, regulatory documents note that alcohol intolerance may signal an increased risk of severe adverse reactions to Metamizole.

Peripheral Anticholinergic Action on Smooth Muscle

This mechanism involves Hyoscine N-butylbromide (HBB) acting as a competitive antagonist at peripheral muscarinic receptors (cholinergic signaling pathway). By blocking the signal that causes contraction, this action directly initiates visceral smooth muscle relaxation (spasmolysis) in the gastrointestinal, biliary, or urinary tracts, which is a core step in modulating the increased tone of smooth muscle tissue.

Central and Peripheral Nociceptive Pathway Modulation

The ingredient Dipyrone (Metamizole) exerts a two-part effect. Its primary action is central, inhibiting the COX-3 enzyme in the nervous system to decrease Prostaglandin E2 ( PGE2) synthesis, thus altering the central processing of nociceptive signals. Additionally, it acts peripherally by modulating intracellular calcium ion release in muscle cells, providing a secondary, non-anticholinergic route to spasmolysis that occurs via a distinct mechanism from HBB's action.

Resulting Physiological Synergy

The simultaneous engagement of two distinct mechanistic domains—receptor-level anticholinergic blockade and enzyme/ion-mediated spasm and nociceptive signal control—engages two distinct mechanistic pathways that contribute to the drug's overall effect profile. This mechanistic synergy results in the simultaneous modulation of cholinergic spasmolytic pathways and central nociceptive signal processing, contributing to the resulting physiological changes within targeted systems.

Buscapina Compositum, a combination of Hyoscine Butylbromide and Sodium Metamizole, is administered via two primary pathways: the oral route using a coated tablet, and the parenteral route using an injectable solution, which is used for both intravenous (IV) and intramuscular (IM) administration. The selection between the oral and injectable forms is based on the required speed and severity of intervention, with parenteral use generally confined to acute, short-term episodes.

The standard adult oral dose is typically one to two tablets per administration. Each tablet usually contains 10 mg of Hyoscine Butylbromide and 250 mg of Sodium Metamizole. The coated tablet must be swallowed whole with sufficient water. The injectable solution, containing 20 mg of Hyoscine Butylbromide and 2.5 g of Metamizole Sodium per 5 mL ampoule, is typically administered as a single 5 mL dose.

The frequency pattern limits administration to a maximum of three times daily, establishing a typical dose interval of approximately eight hours. Special procedural conditions apply to the injectable solution: administration, particularly by the intravenous route, must be performed slowly, and the injection is intended to be given by a qualified healthcare professional.

Dosage may require a reduction for the elderly population and for patients with damaged liver or kidney function, standardizing a principle of cautious initial dosing in vulnerable groups.

Overview of Clinical Evidence

Buscapina Compositum is a combination medication containing the spasmolytic hyoscine butylbromide (also known as scopolamine butylbromide) and the analgesic metamizole (also known as dipyrone). Clinical trials have assessed the combined and individual effects of these components, primarily focusing on pain relief associated with spasms.

---

Efficacy in Pain and Spasm

Research has explored the effectiveness of the combination in relieving acute pain, such as that associated with biliary colic and various postoperative settings. The hyoscine butylbromide component is known to exert a smooth-muscle relaxing effect, which addresses the spasmodic element of pain. Metamizole is a non-opioid analgesic that has been associated with significant pain reduction, often demonstrating comparable effectiveness to other common analgesics, such as ibuprofen, in some acute pain models.

In studies comparing the combination therapy to its individual components, the simultaneous administration has been evaluated for an enhanced antispasmodic and analgesic effect. One trial noted statistically significant symptom improvement when the combined product was used compared to placebo and the analgesic component alone in some instances of abdominal pain.

---

Safety Profile and Adverse Events

Adverse event reporting for the two components differs. Hyoscine butylbromide is generally reported to be well-tolerated with infrequent anticholinergic-related side effects, such as dry mouth or accommodation disturbances. The metamizole component is associated with a risk of agranulocytosis (a severe blood disorder), which is a rare but serious event. Due to this risk, the use of metamizole is restricted or banned in several countries. The reported adverse events for the combination in clinical settings are typically mild, but the overall safety profile must be considered in light of the known risk associated with metamizole.

Key Studies & References

1. Metamizole-induced agranulocytosis: a systematic review of clinical case reports and epidemiological studies

Common questions about Buscapina Compositum (FAQ)

---

Q: What is the standard oral dose in milligrams for the active ingredients?

Official product information states that the standard adult oral dose is typically one to two tablets per administration. Each tablet contains 10 mg of Hyoscine Butylbromide and 250 mg of Sodium Metamizole. The precise milligram amount suitable for an individual’s condition is determined by a healthcare provider.

---

Q: What is the function of the Sodium Metamizole component in this medicine?

The Sodium Metamizole (also known as Dipyrone) component is classified as a non-opioid analgesic. Its primary function, according to regulatory documents, is to relieve severe pain associated with the muscle spasms. This analgesic effect works alongside the spasm-relaxing mechanism of the Hyoscine Butylbromide component.

---

Q: Is there a maximum number of days I should use this injectable medication?

Official labeling generally confines the use of the injectable solution to acute, short-term episodes of pain. Regulatory documents sometimes specify that use is for a limited period, such as no more than a few days, to address severe symptoms. Patients are instructed to follow their prescribing healthcare professional's guidance regarding the duration of treatment.

---

Q: How should I properly dispose of expired Buscapina Compositum?

For safe disposal, it is recommended to use an official drug take-back program when available. If at-home disposal is necessary, guidelines state the medicine should be mixed with an undesirable substance, such as dirt or used coffee grounds, and placed in a sealed container before throwing it in the household trash. The medicine must never be flushed down a toilet or sink.

---

Q: Is it safe to take my oral dose with milk or food?

The official administration instructions state that the coated tablet must be swallowed whole with sufficient water. The labeling typically does not specify administration in relation to food or milk. For specific concerns about administration with food or milk, patients typically refer to the local Patient Information Leaflet (PIL) or seek advice from a healthcare professional.

---

Q: How quickly does the injectable form of Buscapina Compositum start to relieve pain?

The injectable route is chosen when rapid relief for severe pain is desired. Official information indicates a potentially fast onset of action following administration, though individual results may vary. This fast action contributes to the medication's use in acute pain settings.

---

Q: Is Buscapina Compositum available as a suppository or liquid suspension?

The pharmaceutical forms officially documented in regulatory sources are the oral coated tablet and the injectable solution. The availability of other forms, such as suppositories or liquid suspensions, may vary by country. Patients are typically advised to check the specific product information approved by their local regulatory authority.

---

Q: What should I do if I miss a scheduled dose?

If a dose is missed, official patient leaflets generally advise against taking a double dose to compensate. Instead, patients are generally advised to take the next dose at the regularly scheduled time and maintain the required interval between administrations.

---

Q: Is Buscapina Compositum the same as the product Buscopan?

Buscapina Compositum and Buscopan Compositum are often used as brand names for a combination medicine containing Hyoscine Butylbromide and an analgesic component. The specific second ingredient (e.g., Metamizole or Paracetamol) and local brand names can vary significantly by country. It is always important to confirm the exact active ingredients listed on a medicine’s packaging.

Storage Requirements

Official regulatory documents define specific environmental conditions to maintain the stability and integrity of Buscapina Compositum. The product should be stored at a controlled room temperature, typically maintained between 15 C and 30 C (59 F and 86 F), and must be protected from both excessive heat and moisture. The medicine must remain in its original container to ensure full protection until its expiration date.

All medicinal products are required to be stored out of the sight and reach of children.

Disposal Instructions

Disposal must comply with governmental regulations for unused or expired medicines. The recommended method is to use an official drug take-back program. If this option is not available, the product should be prepared for household trash by mixing it with an undesirable substance (such as coffee grounds or dirt) and placing it into a sealed bag or container. The medicine must not be flushed down a toilet or sink.